Skip to main content
SpringerLink
Log in

Matrix metalloproteinase inhibitors

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Matrix metalloproteinases (MMPs) are a family of enzymes responsible for the breakdown of proteins of connective tissue. Through this action they play an important role in growth, development and tissue repair. Recent studies also suggest that MMPs are utilised in cancer, facilitating both local tumour invasion and metastasis. Levels of certain MMPs such as stromelysin-3 and gelatinase are elevated in tumour-associated stroma compared to non- involved tissue. A series of synthetic low molecular weight MMP inhibitors have been produced. Early inhibitors were based on the peptide structure of collagen, although more recently non-peptide inhibitors have also been developed. The inhibitors are selective for the MMP family and are active at low nanomolar concentrations. Experiments in models of breast cancer have shown that MMP inhibitors can significantly reduce the growth rate of both primary and secondary tumours, and can block the process of metastasis. Several MMP inhibitors have now started clinical trials in patients with advanced malignancy. Although not the optimum setting for a tumouristatic agent, early results suggest this approach may be effective in slowing tumour growth. Trials in the adjuvant setting will provide the most important test of these inhibitors and should determine their potential to complement existing cytoreductive treatments and prolong survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Harris J, Morrow M, Norton L: Malignant tumours of the breast. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: Principals and Practice of Oncology, 5th Edition. Lippincott-Raven, New York, 1997, pp 1557-1616

    Google Scholar 

  2. Chu KC, Tarone RE, Kessler LG, Ries LA, Hankey BF, Miller BA, Edwards BK: Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 88:1571-1579, 1996

    Google Scholar 

  3. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P: Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer 73:664-667, 1994

    Google Scholar 

  4. Kleiner DJ, Stetler-Stevenson WG: Structural biochemistry and activation of matrix metalloproteinases. Curr Opin Cell Biol 5:891-897, 1993

    Google Scholar 

  5. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases — structure, regulation and biological functions. Eur J Cell Biol 74:111-122, 1997

    Google Scholar 

  6. Wilhelm SC, Eisen AZ, Teter M, Clark SD, Kronberger A, Goldberg G: Human fibroblast collagenase: glycosylation and tissue-specific levels of enzyme synthesis. Proc Natl Acad Sci USA 83:3756-3760, 1986

    Google Scholar 

  7. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG: Human 92-and 72-kilodalton type IV collagenases are elastases. J Biol Chem 266:7870-7875, 1991

    Google Scholar 

  8. Shapiro SD, Kobayashi DK, Ley TJ: Cloning and characterisation of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem 268:23824-23829, 1993

    Google Scholar 

  9. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370:61-65, 1994

    Google Scholar 

  10. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348:699-704, 1990

    Google Scholar 

  11. Pei D, Majmudar G, Weiss SJ: Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem 269: 25849-25855, 1994

    Google Scholar 

  12. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Woolley K: Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 370:555-557, 1994

    Google Scholar 

  13. Chandler S, Cossins J, Lury J, Wells G: Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour-necrosis factor-α fusion protein. Biochem Biophys Res Commun 228:421-429, 1996

    Google Scholar 

  14. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:729-733, 1997

    Google Scholar 

  15. Moss ML, Jin SL, Milla ME, Burkhart W, Carter HL: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385:733-736, 1997

    Google Scholar 

  16. Beckett RP, Davidson AH, Drummond AH, Huxley P, Whittaker M: Recent advances in matrix metalloproteinase inhibitor research. Drug Dev Today 1:16-26, 1996

    Google Scholar 

  17. Brown PD, Giavazzi R: Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 6:967-974, 1995

    Google Scholar 

  18. Grams F, Crimmin M, Hinnes L, Huxley P, Pieper M, Tschesche H, Bode W: Structure determination and analysis of human neutrophil collagenase complexed with a hydoxamate inhibitor. Biochemistry 34:14012-14020, 1995

    Google Scholar 

  19. Morphy JR, Beeley NRA, Boyce BA: Potent and selective inhibitors of gelatinase A. 2. Carboxylic acids and phosphonic acid derivatives. Bioorg Med Chem Lett 4:2747-2752, 1994

    Google Scholar 

  20. Santos O, McDermott CD, Daniels RG, Appelt K: Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin Exp Met 15: 499-508, 1997

    Google Scholar 

  21. Collier MA, Yuen GJ, Bansal SK, Kolis S, Chew TG, Appelt K, Clendeninn NJ: A phase I study of the matrix metalloproteinase (MMP) inhibitor AG3340 given in single doses to healthy volunteers. Proc Am Assoc Cancer Res 38:13, 1997

    Google Scholar 

  22. Lewis EJ, Bishop J, Bottomley KMK, Bradshaw D, Brewster M, Broadhurst MJ, Brown PA, Budd JM, Elliott L, Greenham AK, Johnson WH, Nixon JS, Rose F, Sutton B, Wilson K: Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 121:540-546, 1997

    Google Scholar 

  23. Wood ND, Aitken M, Harris S, Kitchener S, McClelland GR, Sharp S: The tolerability and pharmacokinetics of the cartilage protective agent (Ro32-3555) in healthy male volunteers. Br J Clin Pharm 42:676-677, 1996

    Google Scholar 

  24. Beckett RP: Recent advances in the field of matrix metalloproteinase inhibitors (patent update). Exp Opin Ther Patents 6:1305-1315, 1996

    Google Scholar 

  25. Lee H-J, Chung M-C, Lee C-H, Yun B-S, Chun H-K, Kho Y-H: Gelastatins A and B, new inhibitors of gelatinase A from Westerdykella multispora F50733. J Antibiot 50:357-359, 1996

    Google Scholar 

  26. Naito K, Nakajima S, Kanbayashi N, Okuyama A, Goto M: Inhibition of metalloproteinase activity of rheumatoid arthritis synovial cells by a new inhibitor [BE16627B; L-N-(N-hydroxy-2-isobutylsuccinamoyl)-seryl-L-valine]. Agents Actions 39:182-186, 1993

    Google Scholar 

  27. Golub LM, McNamara TF, D'Angelo G, Greenwald RA, Ramamurthy NS: A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dental Res 66:1310-1314, 1987

    Google Scholar 

  28. Reich R, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC, Miskin R: Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 48:3307-3312, 1988

    Google Scholar 

  29. Chirivi RS, Garofalo A, Crimmin MJ, Bawden LJ, Brown PD, Giavazzi RG: Inhibition of the metastatic spread and growth of B16–BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58:460-464, 1994

    Google Scholar 

  30. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumour growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54:4726-4728, 1994

    Google Scholar 

  31. An Z, Wang X, Willmott N, Chander SK, Tickle S, Docherty AJP, Mountain A, Millican AT, Morphy R, Porter JR, Epemolu RO, Kubota T, Moossa AR, Hoffman RM: Conversion of a highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Met 15: 184-195, 1997

    Google Scholar 

  32. Moses MA, Sudhalter J, Langer R: Identification of an inhibitor of neovascularization from cartilage. Science 248:1408-1410, 1990

    Google Scholar 

  33. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown P, Giavazzi R: Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87:293-298, 1995

    Google Scholar 

  34. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD: Control of lymphatic and hematogenous metastases of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56:2815-2822, 1996

    Google Scholar 

  35. Sledge GW, Qulali M, Goulet R, Bone EA, Fife R: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Res 87: 1546-1550, 1995.

    Google Scholar 

  36. Galardy RE, Cassabone ME, Giese C, Gilbert JH, Lapierre F, Lopez H, Scaefer ME, Stack R, Sullivan M, Summers B, Tressler R, Tyrrell D, Wee J, Allen SD, Castellot JJ, Barletta JP, Schultz G, Fernandez LA, Fisher S, Cui T-Y, Foellmer HG, Grobelny D, Holleran WM: Low molecular weight inhibitors in corneal ulceration. Ann NY Acad Sci 732:315-323, 1994

    Google Scholar 

  37. Macaulay VM, O'Byrne KJ, Saunders MP, Salisbury A, Long L, Gleeson F, Ganesan TS, Harris AL, Talbot DC: Phase I study of matrix metalloproteinase (MMP) inhibitor batimastat (BB-94) in patients with malignant pleural effusions. Br J Cancer 71:11, 1995

    Google Scholar 

  38. Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, Sale M, McCann, P, Moore J, Cole A, Hawkins MJ: Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 14:193-202, 1996

    Google Scholar 

  39. Lauhio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H: Double-blind, placebo-controlled study of the three month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 24:6-14, 1991

    Google Scholar 

  40. Greenwald RA, Moak SA, Golub LM: Low dose doxycycline inhibits pyridinoline excretion in selected patients with rheumatoid arthritis. Ann NY Acad Sci 732:419-421, 1994

    Google Scholar 

  41. Millar AW, Brown PD, Moore J, Galloway WA, Cornish AG, Lenehan TJ, Lynch KP: Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharm, in press

  42. Goldenberg DM, Neville A, Carter A: CEA (carcinoembryonic antigen): Its role as a marker in the management of cancer. J Cancer Res Clin Oncol 101:239-242, 1981

    Google Scholar 

  43. Steinberg W, Gelfand R, Anderson K: Comparison of the sensitivity and specificity of the CA 19-9 and CEA assays in detecting cancer of the pancreas. Gastroenterology 90:343-349, 1986

    Google Scholar 

  44. Rubin SC, Hoskins WJ, Hakes TB: CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol 160:667-671, 1989

    Google Scholar 

  45. Stamey TA, Kabalin JW, McNeal JE: Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 141:1076-1083, 1989

    Google Scholar 

  46. Millar A, Brown P: 360 patient meta-analysis of studies of marimastat, a novel matrix metalloproteinase inhibitor. Ann Oncol 7:123, 1996

    Google Scholar 

  47. Poole C, Adams M, Barley V, Graham J, Kerr D, Louviaux I, Perren T, Piccart M, Thomas H: A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced ovarian cancer. Ann Oncol 7:68, 1996

    Google Scholar 

  48. Primrose J, Bleiberg H, Daniel F, Johnson P, Mansi J, Neoptolemos J, Seymour M, Van Belle S: A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced colorectal cancer. Ann Oncol 7:35, 1996

    Google Scholar 

  49. Parsons SL, Watson SA, Griffin NR, Steele RJC: An open phase I/II study of the oral matrix metalloproteinase inhibitor marimastat in patients with inoperable gastric cancer. Ann Oncol 7:47, 1996

    Google Scholar 

  50. Thomas H, Adams M: A phase I clinical trial of the MMP inhibitor, marimastat, administered concurrently with carboplatin to patients with relapsed ovarian cancer. Eur J Cancer 33:S246, 1997

    Google Scholar 

  51. Anderson IC, Shipp MA, Docherty AJP, Teicher BA: Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 56:715-718, 1996

    Google Scholar 

  52. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Janicke F, Klijn JGM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52:6101-6105, 1992

    Google Scholar 

  53. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer MD, Janicke F, Kiljn JGM: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648-1658, 1994

    Google Scholar 

  54. Alderson MR, Hamlin I, Staunton MD: The relative significance of prognostic factors in breast carcinoma. Br J Cancer 25:646-656, 1971

    Google Scholar 

  55. Van Bogaert L-J, Maldague P: Scirrhous carcinoma of the female breast. Invest Cell Pathol 3:377-382, 1980

    Google Scholar 

  56. Anastassiades OT, Pryce PM: Fibrosis as an indication of time in infiltrating breast cancer and its importance in prognosis. Br J Cancer 29:232-239, 1974

    Google Scholar 

  57. Parham DM, Hagen N, Brown RA: Simplified method of grading primary carcinomas of the breast. J Clin Pathol 45:517-520, 1992

    Google Scholar 

  58. Carlomagno C, Perrone F, Lauria R, De Laurentiis M, Gallo C, Morabito A, Pettinato G, Panico L, Bellelli T, Apicella A, Petrella G, Bianco A, De Placido S: Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer. Oncology 52: 272-277, 1995

    Google Scholar 

  59. Takei H, Iino Y, Horiguchi J, Yakoe T: Immunohistochemical fibronectin staining pattern and prognosis in invasive breast carcinoma. Oncology 52:106-111, 1995

    Google Scholar 

Download references

Authors
  1. Peter D. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brown, P.D. Matrix metalloproteinase inhibitors. Breast Cancer Res Treat 52, 125–136 (1998). https://doi.org/10.1023/A:1006119319695

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006119319695

Search

Navigation